Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies – Executive summary

Authors

  • Andrea Kokorovic
  • Alan I. So
  • Hosam Serag
  • Christopher French
  • Robert J. Hamilton
  • Jason P. Izard
  • Jasmir G. Nayak
  • Fréderic Pouliot
  • Fred Saad
  • Bobby Shayegan
  • Armen Aprikian
  • Ricardo A. Rendon

DOI:

https://doi.org/10.5489/cuaj.7357

Keywords:

ADT, prostate cancer, CV risk, bone health, HRQOL

Abstract

Androgen deprivation therapy (ADT) plays an important role in the contemporary management of prostate cancer (PCa) across various stages of the disease. While ADT remains a highly effective treatment for PCa, it is not curative, and its use is associated with significant adverse events that span across various organ systems.

Downloads

Download data is not yet available.

Downloads

Published

2021-05-31

How to Cite

Kokorovic, A. ., So, A. I. ., Serag, H. ., French, C. ., Hamilton, R. J. ., Izard, J. P. ., Nayak, J. G. ., Pouliot, F. ., Saad, F. ., Shayegan, B. ., Aprikian, A. ., & Rendon, R. A. . (2021). Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies – Executive summary. Canadian Urological Association Journal, 15(6), 159–61. https://doi.org/10.5489/cuaj.7357

Issue

Section

CUA Guideline